Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 [Yahoo! Finance...
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: Yahoo! Finance
LUND, SE / ACCESSWIRE / September 13, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology (ESMO) Annual Congress 2024, taking place September 13th - 17th, 2024 in Barcelona, Spain. Presentation Details Poster number: #668P Title: First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease Presenter: Thomas Marron, MD, PhD Date: Saturday, September 14th, 2024 About the Trial The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label dose-escalation trial that w
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Aptevo Therapeutics files $100M mixed securities shelf [Seeking Alpha]Seeking Alpha
- Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025Accesswire
- Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross ProceedsAccesswire
- 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial [Yahoo! Finance]Yahoo! Finance
- 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML TrialAccesswire
APVO
Sec Filings
- 2/14/25 - Form S-3
- 2/14/25 - Form 10-K
- 2/14/25 - Form 8-K
- APVO's page on the SEC website